Logo

Concord Biotech Share Price

NSE: CONCORDBIO
|
Pharmaceuticals
₹ 1,274.90
-₹11.20 (-0.87%)
1D
Last updated 03 Jul, 2026, 15:53 IST

Concord Biotech Share Price Today

As of 5 Jul 2026, Concord Biotech share price is ₹1,274.90. The stock opened at ₹1,288.10, compared to its previous close of ₹1,286.10. During today's trading session, Concord Biotech share price moved in the range of ₹1,260.00 to ₹1,295.10, with an average price of ₹1,277.55 for the day. Looking at its last 52-week, the stock has touched a low of ₹987.00 and a high of ₹1,980.00. On the performance front, Concord Biotech share price has declined by 2.79% over the last six months and is down 27.16% on a year-on-year basis.

₹1,260.00
0.87% down today
₹1,295.10
1D LOW
1D HIGH

Concord Biotech Returns Calculator

Open
₹1,288.10
High
₹1,295.10
Low
₹1,260.00
Prev. close
₹1,286.10
Circuit
L
H
₹1,020.00
₹1,529.80
52-week
L
H
₹987.00
₹1,980.00

Concord Biotech Shareholder Returns

Concord Biotech Share Price History

Mkt Cap Cr
13,435.30
P/E
51.83
P/B
6.66
ROE
12.94%
D/E
0.00
ROCE
17.08%
Div. Yield
0.59%
EPS(TTM)
25.17
Turnover
0.51
EV/EBITDA
32.06
Net Margin
0.00%
Op. Margin
0.00%
ROA
11.60%
Quick Ratio
0.00
Curr. Ratio
7.45
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Concord Biotech outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Concord Biotech appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Concord Biotech earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Zydus Lifesciences1,10,651.0021.604.0818.59%0.3117.35%235.250.09%0.3935.38
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Mankind Pharma1,02,729.0053.006.3011.74%0.3413.13%397.020.04%0.5449.37
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

Concord Biotech Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹1,200.09₹1,016.94₹853.17₹712.93
Other Income₹44.45₹33.78₹35.31₹23.42
Total Revenue₹1,244.53₹1,050.72₹888.48₹736.35
Total Expenses₹748.66₹641.53₹568.42₹495.19
Profit Before Tax₹494.55₹412.57₹322.01₹237.52
Tax₹122.91₹104.46₹81.93₹62.59
Profit After Tax₹371.64₹308.10₹240.09₹174.93
EPS - Basic₹35.52₹29.45₹22.95₹16.72
EPS - Diluted₹35.52₹29.45₹22.95₹16.72

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹494.55₹412.57₹322.01₹237.52
Income before WC changes₹524.69₹450.00₹368.56₹290.31
Change in Assets-₹216.44-₹73.97-₹79.46-₹70.11
Change in Liabilities₹45.68-₹7.21₹27.17₹48.06
Change in WC-₹170.76-₹81.18-₹52.29-₹22.06
Cash flow from Operations₹244.52₹265.47₹246.00₹207.47
Cash flow from Investing-₹159.99-₹154.61-₹157.95-₹111.79
Cash flow from Financing-₹98.77-₹99.21-₹85.22-₹100.16
Total Cash Flow-₹14.24₹11.64₹2.83-₹4.48
Cash (Start of the year)₹15.14₹3.50₹0.67₹5.14
Cash (End of the year)₹0.90₹15.14₹3.50₹0.67

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹899.01₹804.48₹786.28₹680.13
Current Assets₹1,135.24₹896.23₹727.70₹632.67
Total Assets₹2,034.25₹1,700.71₹1,513.98₹1,312.79
Current Liabilities₹184.06₹142.16₹191.84₹155.17
Net Current Asset₹951.18₹754.08₹535.86₹477.50
Non-Current Liabilities₹37.47₹31.91₹32.14₹54.40
Equity Capital₹1,812.72₹1,526.65₹1,290.00₹1,103.22
Total Equity & Liabilities₹2,034.25₹1,700.71₹1,513.98₹1,312.79

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹1,200.09₹1,016.94₹853.17₹712.93
Other Income₹44.45₹33.78₹35.31₹23.42
Total Revenue₹1,244.53₹1,050.72₹888.48₹736.35
Total Expenses₹748.66₹641.53₹568.42₹495.19
Profit Before Tax₹495.88₹409.19₹320.05₹241.16
Tax₹122.91₹104.46₹81.93₹62.59
Profit After Tax₹372.96₹304.73₹238.13₹178.57
EPS - Basic₹35.65₹29.13₹22.76₹17.07
EPS - Diluted₹35.65₹29.13₹22.76₹17.07

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹495.88₹409.19₹320.05₹241.16
Income before WC changes₹524.69₹450.00₹368.56₹290.31
Change in Assets-₹216.44-₹73.97-₹79.46-₹70.11
Change in Liabilities₹45.68-₹7.21₹27.17₹48.06
Change in WC-₹170.76-₹81.18-₹52.29-₹22.06
Cash flow from Operations₹244.52₹265.47₹246.00₹207.47
Cash flow from Investing-₹159.99-₹154.61-₹157.95-₹111.79
Cash flow from Financing-₹98.77-₹99.21-₹85.22-₹100.16
Total Cash Flow-₹14.24₹11.64₹2.83-₹4.48
Cash (Start of the year)₹15.14₹3.50₹0.67₹5.14
Cash (End of the year)₹0.90₹15.14₹3.50₹0.67

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹898.94₹803.08₹786.95₹680.79
Current Assets₹1,135.24₹896.23₹727.70₹632.67
Total Assets₹2,034.18₹1,699.32₹1,514.65₹1,313.46
Current Liabilities₹184.06₹142.16₹190.53₹151.89
Net Current Asset₹951.18₹754.08₹537.17₹480.77
Non-Current Liabilities₹37.47₹31.91₹32.14₹54.40
Equity Capital₹1,812.65₹1,525.25₹1,291.98₹1,107.16
Total Equity & Liabilities₹2,034.18₹1,699.32₹1,514.65₹1,313.46
* All values are in INR Crore
Qty
Bid
52
1274.9
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 52
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
2
Neutral
2
Bullish
4
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
52.11
Neutral
ATR (14)
42.7
Neutral
STOCH(9,6)
15.64
Bullish
STOCH RSI (14)
6.35
Bullish
ADX(9)
21.62
Bearish
UO(9)
29.66
Bullish
ROC(12)
-7.27
Bearish
WillR(14)
-87.44
Bullish
Period
Simple value
Exponential vaue
5D
1277.86
1282.91
10D
1293.69
1289.56
20D
1304.3
1278.03
50D
1201.36
1227.2
100D
1165.63
1218.38

About Concord Biotech

Concord Biotech logo
ISIN
INE338H01029
Sector Market Cap
₹ 13,435.3 Cr

Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.

Concord Biotech Financial Highlights

  • Revenue: Concord Biotech reported revenue of ₹1,107.25 crore in FY26 vs ₹1,244.54 crore in FY25. It showed a decrease of 11.03% on a yearly basis.
  • Operating Profit: Concord Biotech reported an operating profit of ₹344.65 crore in FY26 vs ₹494.55 crore in FY25. It showed a decrease of 30.31% on a year-on-year basis.
  • Net Profit: Concord Biotech reported a net profit of ₹259.23 crore in FY26 vs ₹371.64 crore in FY25. It showed a decrease of 30.25% on a yearly basis.

Concord Biotech Quarterly Result Highlights

  • Concord Biotech reported revenue of ₹341.43 crore in Mar 2026, compared with ₹287.75 crore in Dec 2025, representing an increase of 18.66% on a quarter-on-quarter (QoQ) basis.
  • Concord Biotech reported an operating profit of ₹114.08 crore in Mar 2026, compared with ₹86.16 crore in Dec 2025, representing an increase of 32.40% on a quarter-on-quarter (QoQ) basis.
  • Concord Biotech reported a profit of ₹88.47 crore in Mar 2026, compared with ₹63.64 crore in Dec 2025, reflecting an increase of 39.02% on a QoQ basis.
  • The earnings per share (EPS) of Concord Biotech stood at ₹35.52 during Mar 2026.
Know more
Promoters
44.08%
FII
7.80%
Other DII
4.92%
Retail and other
38.90%
Mutual funds
4.30%
Foreign institutions - FII
Compare against other stocks
Concord Biotech logo
Concord Biotech
Pharmaceuticals
Add Stock
Add Another

FAQs on Concord Biotech Share Price